Setting up the Right Scenarios for Cost-Effectiveness Analysis: An Example with Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients in China
Y Wan, ZG Lu, F Chen, J Chen - Value in Health, 2014 - valueinhealthjournal.com
Objectives Warfarin, the standard oral anticoagulant for stroke prevention in patients with
atrial fibrillation (AF), is associated with frequent international normalized ratio (INR) …
atrial fibrillation (AF), is associated with frequent international normalized ratio (INR) …
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the …
M van Hulst, J Stevanovic, MS Jacobs… - Journal of Medical …, 2018 - Taylor & Francis
Background: Atrial fibrillation (AF) causes a significant health and economic burden to the
Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better …
Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better …
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic
AK Adcock, JK Lee-Iannotti, MI Aguilar… - The …, 2012 - journals.lww.com
Background: Warfarin has provided protection against cardioembolic stroke in the setting of
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …
[引用][C] Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke …
Cost of dabigatran for atrial fibrillation
BF Gage - BMJ, 2011 - bmj.com
Because atrial fibrillation is associated with advanced age and obesity, its prevalence is
increasing worldwide. 1 New treatments such as ablation and left atrial occlusion may …
increasing worldwide. 1 New treatments such as ablation and left atrial occlusion may …
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
G Chalikias, N Diehm - Advances in Venous Arterial …, 2011 - search.proquest.com
The authors of the present work extracted data from trials of anticoagulant therapy in order to
estimate the cost-effectiveness of dabigatran compared with warfarin for the prevention of …
estimate the cost-effectiveness of dabigatran compared with warfarin for the prevention of …
Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation
MG Celeste, F De Marco… - …, 2017 - journals.seedmedicalpublishers.com
BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated
for the prevention of thromboembolic events in patients with Non-Valvular Atrial Fibrillation …
for the prevention of thromboembolic events in patients with Non-Valvular Atrial Fibrillation …
[HTML][HTML] Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients …
L Nshimyumukiza, J Duplantie, M Gagnon, X Douville… - Thrombosis journal, 2013 - Springer
Background Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading
cause of stroke and systemic embolism. Chronic anticoagulation is recommended for …
cause of stroke and systemic embolism. Chronic anticoagulation is recommended for …
Cost-effectiveness analysis of apixaban versus dabigatran for prevention of stroke in patients with non-valvular atrial fibrillation in spain
LB Nicolás, CC Fontcuberta… - European journal of …, 2014 - dialnet.unirioja.es
Objective: To assess the cost-effectiveness of apixaban vs. dabigatran in stroke prevention
in patients with non-valvular atrial fibrillation (NVAF) in Spain. Method: A Markov model was …
in patients with non-valvular atrial fibrillation (NVAF) in Spain. Method: A Markov model was …